Cue Biopharma (NASDAQ:CUE) had its target price upped by Oppenheimer from $27.00 to $32.00 in a research report released on Wednesday morning, AnalystRatings.com reports. Oppenheimer currently has an outperform rating on the stock.
Several other analysts also recently commented on the stock. ValuEngine upgraded shares of Cue Biopharma from a sell rating to a hold rating in a report on Tuesday, March 3rd. BTIG Research assumed coverage on shares of Cue Biopharma in a report on Tuesday, January 28th. They issued a buy rating for the company. Zacks Investment Research downgraded shares of Cue Biopharma from a buy rating to a hold rating in a report on Monday, May 11th. BidaskClub upgraded shares of Cue Biopharma from a buy rating to a strong-buy rating in a report on Saturday, April 25th. Finally, JMP Securities raised their price objective on shares of Cue Biopharma from $22.00 to $30.00 and gave the stock an outperform rating in a report on Friday, March 6th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of Buy and a consensus target price of $28.00.
Shares of Cue Biopharma stock traded down $0.44 during trading hours on Wednesday, reaching $30.10. The company’s stock had a trading volume of 174,265 shares, compared to its average volume of 346,266. Cue Biopharma has a one year low of $6.54 and a one year high of $30.99. The company has a market capitalization of $868.11 million, a P/E ratio of -18.85 and a beta of 2.25. The stock’s fifty day simple moving average is $22.11 and its two-hundred day simple moving average is $16.41.
Cue Biopharma (NASDAQ:CUE) last released its quarterly earnings data on Tuesday, May 19th. The company reported ($0.48) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.15). Cue Biopharma had a negative net margin of 959.08% and a negative return on equity of 103.99%. As a group, equities analysts forecast that Cue Biopharma will post -1.33 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in the company. Corriente Advisors LLC boosted its position in shares of Cue Biopharma by 187.7% in the first quarter. Corriente Advisors LLC now owns 820,000 shares of the company’s stock valued at $11,636,000 after acquiring an additional 535,000 shares during the period. Prosight Management LP boosted its position in shares of Cue Biopharma by 301.1% in the first quarter. Prosight Management LP now owns 552,060 shares of the company’s stock valued at $7,834,000 after acquiring an additional 414,432 shares during the period. State Street Corp boosted its position in shares of Cue Biopharma by 11.4% in the first quarter. State Street Corp now owns 371,783 shares of the company’s stock valued at $5,276,000 after acquiring an additional 38,082 shares during the period. Geode Capital Management LLC boosted its position in shares of Cue Biopharma by 17.2% in the first quarter. Geode Capital Management LLC now owns 308,587 shares of the company’s stock valued at $4,378,000 after acquiring an additional 45,381 shares during the period. Finally, Crestwood Advisors Group LLC bought a new position in shares of Cue Biopharma in the fourth quarter valued at approximately $4,286,000. Institutional investors own 37.21% of the company’s stock.
About Cue Biopharma
Cue Biopharma, Inc, a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers.
Featured Article: Portfolio Manager
Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.